3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
292
Urinary Bladder Neoplasms
39
Neoplasm Metastasis
35
Carcinoma, Non-Small-Cell Lung
24
Carcinoma, Transitional Cell
23
Neoplasms
21
Breast Neoplasms
20
Lung Neoplasms
13
Carcinoma, Renal Cell
13
Ovarian Neoplasms
12
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Non-Muscle Invasive Bladder Neoplasms
10
Melanoma
9
Small Cell Lung Carcinoma
7
Salivary Gland Neoplasms
7
Prostatic Neoplasms, Castration-Resistant
7
Head and Neck Neoplasms
7
Esthesioneuroblastoma, Olfactory
7
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Urethral Neoplasms
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Prostate Cancer Metastatic
5
Pancreatic Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Kidney Neoplasms
5
Adenocarcinoma
5
Sarcoma
4
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cystectomy
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Microscopy
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
Docetaxel
×
Genitourinary
×
Clear all
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts